Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Characterization of Chronic and Unremitting Symptoms in Long Term Survivors of Head and Neck Cancer

Head/Neck

Head/Neck
N/A
Murphy, Barbara
VICCSUPP1488

Construction and Validation of an Oral Health Screening Tool in Head and Neck Cancer Survivors Who Received Chemotherapy or Radiotherapy

Multiple Cancer Types

Head/Neck, Supportive Care
N/A
Smith, Derek
VICCSUPP19107

Patient Perspectives about Discussing Financial Toxicity in Head and Neck Cancer

Head/Neck

Head/Neck
N/A
Langerman, Alexander
VICCSUPP19116

Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients

Multiple Cancer Types

Head/Neck, Lung
N/A
Weinger, Matthew
VICCMD1998

Head and Neck Tumor Tissue Repository and Clinical Database

Head/Neck

Head/Neck
N/A
Kim, Young Jun
NCT00898638
VICCHN0356

Artificial Tears for the Reduction of Radioiodine Levels in the Nasolacrimal Duct System of Patients with Thyroid Carcinoma following Radioiodine Therapy

Head/Neck

This phase II trial studies how well artificial tears works in reducing radioiodine levels in the nasolacrimal duct system in patients with thyroid carcinoma following radioiodine therapy. Radioactive iodine therapy for thyroid carcinoma has been associated with nasolacrimal duct obstruction. Artificial tears may dilute the amount of radioactive iodine in the tears of the eyes, thus decreasing uptake by the cells lining the nasolacrimal duct system.
Head/Neck
II
Sobel, Rachel
NCT04327999
VICCHN2018

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Head/Neck

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III / IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves major pathological response and event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
Head/Neck
III
Gibson, Mike
NCT03765918
VICCHN1861

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer

Head/Neck

This phase II / III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy and radiation therapy followed by maintenance nivolumab therapy works better than chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal cancer.
Head/Neck
II/III
Gibson, Mike
NCT03811015
ECOGHNEA3161

Neuroinflammation in Chronic Systemic Symptoms in Patients with Head and Neck Cancer

Head/Neck

This study investigates markers of neuroinflammation in chronic systemic symptoms (CSS) in patients with head and neck cancer. CSS includes fatigue, neurocognitive dysfunction, centralized pain, mood disorders, sleep disturbances, and hypothalamic dysfunction manifested as thermal discomfort or hyperhidrosis (excessive sweating). Knowledge gained from this study may contribute to improving treatments for patients with CSS.
Head/Neck
N/A
Schoenburg, Poppy
NCT04636723
VICCHN20100

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Head/Neck

An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in subjects with HRAS mutant HNSCC participating in Cohort 1 in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
Head/Neck
II
Gibson, Mike
NCT03719690
VICCHN18117

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: